Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?
暂无分享,去创建一个
A. Kiselev | A. Sheptulina | Anastasia Yu. Elkina | J. Golubeva | Ekaterina O. Liusina | Anton R. Kiselev | Oxana M. Drapkina | O. Drapkina | E. O. Liusina
[1] J. Linseisen,et al. Association between fatty liver index and blood coagulation markers: a population-based study , 2023, Lipids in Health and Disease.
[2] A. Vallée. Associations between smoking and alcohol consumption with blood pressure in a middle-aged population , 2023, Tobacco induced diseases.
[3] R. Francés,et al. The shaping of gut immunity in cirrhosis , 2023, Frontiers in Immunology.
[4] Annet Kirabo,et al. Gut microbiota dependant trimethylamine N-oxide and hypertension , 2023, Frontiers in Physiology.
[5] F. Marques,et al. A major mechanism for immunomodulation: Dietary fibres and acid metabolites. , 2023, Seminars in immunology.
[6] D. Monleón,et al. Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease , 2023, World journal of clinical cases.
[7] Young Mee Kim,et al. Effects of SCFAs and TMAO on non-alcoholic fatty liver disease indicating the therapeutic benefits of plant-based diet, and supplemental prebiotics, probiotics and synbiotics , 2023, Applied Biological Chemistry.
[8] Haofei Hu,et al. Association Between Hypertension and New-Onset Non-Alcoholic Fatty Liver Disease in Chinese Non-Obese People: A Longitudinal Cohort Study , 2023, Diabetes, metabolic syndrome and obesity : targets and therapy.
[9] M. Trauner,et al. The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation , 2023, Scientific Reports.
[10] R. Kreutz,et al. Sex and gender in hypertension guidelines , 2023, Journal of Human Hypertension.
[11] Beata Franczyk,et al. Does the Composition of Gut Microbiota Affect Hypertension? Molecular Mechanisms Involved in Increasing Blood Pressure , 2023, International journal of molecular sciences.
[12] L. Cugusi,et al. Gender Differences and Cardiometabolic Risk: The Importance of the Risk Factors , 2023, International journal of molecular sciences.
[13] I. Mogilnicka,et al. Trimethylamine, a gut bacteria metabolite and air pollutant, increases blood pressure and markers of kidney damage including proteinuria and KIM-1 in rats , 2022, Journal of Translational Medicine.
[14] C. Tsioufis,et al. Fatty liver index and cardiovascular outcomes in never-treated hypertensive patients: a prospective cohort , 2022, Hypertension Research.
[15] H. Lee,et al. Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years , 2022, Cardiovascular Diabetology.
[16] Jibo He,et al. The Additive Values of the Classification of Higher Serum Uric Acid Levels as a Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease , 2022, Nutrients.
[17] J. Cai,et al. Severity of Nonalcoholic Fatty Liver Disease is Associated With Cardiovascular Outcomes in Patients With Prehypertension or Hypertension: A Community–Based Cohort Study , 2022, Frontiers in Endocrinology.
[18] E. J. Belin de Chantemèle,et al. Salt Sensitivity of Blood Pressure in Women , 2022, Hypertension.
[19] A. Sanyal,et al. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality , 2022, Frontiers in Cardiovascular Medicine.
[20] D. Roccarina,et al. Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension. , 2022, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[21] M. Mahtab,et al. Gender Differences in Nonalcoholic Fatty Liver Disease , 2022, Euroasian journal of hepato-gastroenterology.
[22] Yang Zou,et al. Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population , 2022, BMC Gastroenterology.
[23] Miyang Luo,et al. Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease , 2022, Frontiers in Immunology.
[24] Qingzhi Huang,et al. Association between hypertension and nonalcoholic fatty liver disease: a cross-sectional and meta-analysis study , 2022, Journal of Human Hypertension.
[25] A. Leite-Moreira,et al. Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review , 2022, Metabolites.
[26] G. Nam,et al. Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease , 2022, Journal of obesity & metabolic syndrome.
[27] Gerui Li,et al. Bidirectional Association between Hypertension and NAFLD: A Systematic Review and Meta-Analysis of Observational Studies , 2022, International journal of endocrinology.
[28] C. Delles,et al. Sex Differences in the Prevalence, Outcomes and Management of Hypertension , 2022, Current Hypertension Reports.
[29] Longjian Liu,et al. The association between bilirubin and hypertension among a Chinese ageing cohort: a prospective follow-up study , 2022, Journal of translational medicine.
[30] Haiyang Tang,et al. Gut Microbial Metabolite Trimethylamine N-Oxide Aggravates Pulmonary Hypertension. , 2022, American journal of respiratory cell and molecular biology.
[31] Ju-Mi Lee,et al. The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients , 2022, International journal of environmental research and public health.
[32] M. Thursz,et al. The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease , 2022, International journal of molecular sciences.
[33] A. Aloisi,et al. Estrogens and phytoestrogens in body functions , 2021, Neuroscience & Biobehavioral Reviews.
[34] Xi Yang,et al. Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy , 2021, Frontiers in Cardiovascular Medicine.
[35] L. Poretsky,et al. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) , 2021, Metabolism open.
[36] G. Mancia,et al. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis , 2021, European journal of gastroenterology & hepatology.
[37] Xiaoming Tu,et al. The Role of Short-Chain Fatty Acids of Gut Microbiota Origin in Hypertension , 2021, Frontiers in Microbiology.
[38] S. Ishihara,et al. Enteric Microbiota-Mediated Serotonergic Signaling in Pathogenesis of Irritable Bowel Syndrome , 2021, International journal of molecular sciences.
[39] S. Della Torre. Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology , 2021, Cells.
[40] A. Patzak,et al. Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin II–induced hypertension , 2021, Redox biology.
[41] F. Galletti,et al. Serum leptin is associated with increased pulse pressure and the development of arterial stiffening in adult men: results of an eight-year follow-up study , 2021, Hypertension Research.
[42] F. Soriguer,et al. Fatty liver index as a predictor for type 2 diabetes in subjects with normoglycemia in a nationwide cohort study , 2021, Scientific Reports.
[43] Marenao Tanaka,et al. Elevated Fatty Liver Index Is Independently Associated With New Onset of Hypertension During a 10‐Year Period in Both Male and Female Subjects , 2021, Journal of the American Heart Association.
[44] Bingong Li,et al. Relationship between Plasma Trimethylamine N-Oxide Levels and Renal Dysfunction in Patients with Hypertension , 2021, Kidney and Blood Pressure Research.
[45] A. Hekmatdoost,et al. The association between epicardial adipose tissue and non-alcoholic fatty liver disease: A systematic review of existing human studies , 2021, EXCLI journal.
[46] H. Degirmenci,et al. Predictors of left atrial remodeling in newly diagnosed hypertensive patients: a speckle-tracking echocardiographic study , 2021, The International Journal of Cardiovascular Imaging.
[47] D. Seals,et al. Gut Microbiome-Derived Metabolite Trimethylamine N-Oxide Induces Aortic Stiffening and Increases Systolic Blood Pressure With Aging in Mice and Humans , 2021, Hypertension.
[48] Feng Ma,et al. Role of Steroid Hormones in the Pathogenesis of Nonalcoholic Fatty Liver Disease , 2021, Metabolites.
[49] B. Zhong,et al. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis , 2021, Lipids in Health and Disease.
[50] Hao-Jie Zhong,et al. Risk Factors for Intestinal Barrier Impairment in Patients With Essential Hypertension , 2021, Frontiers in Medicine.
[51] C. Borghi,et al. Uric Acid and Hypertension: Prognostic Role and Guide for Treatment , 2021, Journal of clinical medicine.
[52] A. Sîngeap,et al. Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications , 2021, Canadian journal of gastroenterology & hepatology.
[53] J. Viikari,et al. Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) , 2021, Annals of medicine.
[54] Chongyang Ma,et al. The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis , 2021, Bioengineered.
[55] K. Gariani,et al. Pathophysiology of NASH in endocrine diseases , 2021, Endocrine connections.
[56] Yong‐ho Lee,et al. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[57] C. Byrne,et al. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. , 2020, Diabetes & metabolism.
[58] P. Chun. Therapeutic effects of histone deacetylase inhibitors on heart disease , 2020, Archives of Pharmacal Research.
[59] A. Masclee,et al. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta‐analysis , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[60] A. Anwar,et al. Correlation Between Body Mass Index and Blood Pressure Levels Among Hypertensive Patients: A Gender-Based Comparison , 2020, Cureus.
[61] M. Nieuwdorp,et al. Gut Microbiota in Hypertension and Atherosclerosis: A Review , 2020, Nutrients.
[62] A. Sherman,et al. Endothelial dysfunction due to selective insulin resistance in vascular endothelium: insights from mechanistic modeling. , 2020, American journal of physiology. Endocrinology and metabolism.
[63] М. И. Туровец,et al. Влияние неалкогольной жировой болезни печени на показатели артериальной жесткости и риск сердечно-сосудистых осложнений у пациентов с артериальной гипертензией , 2020 .
[64] A. Cox,et al. Trimethylamine N-oxide: heart of the microbiota–CVD nexus? , 2020, Nutrition Research Reviews.
[65] T. Goeser,et al. NAFLD and cardiovascular diseases: a clinical review , 2020, Clinical Research in Cardiology.
[66] K. Guan,et al. Role of Leptin in Cardiovascular Diseases , 2020, Frontiers in Endocrinology.
[67] L. Schomburg,et al. Selenium and Copper as Biomarkers for Pulmonary Arterial Hypertension in Systemic Sclerosis , 2020, Nutrients.
[68] Xuan Li,et al. Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. , 2020, The Canadian journal of cardiology.
[69] H. El‐Serag,et al. Women have Lower Risk of Nonalcoholic Fatty Liver Disease but Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[70] F. Wei,et al. Higher Serum Uric Acid Level Predicts Non-alcoholic Fatty Liver Disease: A 4-Year Prospective Cohort Study , 2020, Frontiers in Endocrinology.
[71] I. Seong,et al. A Close Relationship between Non-Alcoholic Fatty Liver Disease Marker and New-Onset Hypertension in Healthy Korean Adults , 2020, Korean circulation journal.
[72] M. Lanaspa,et al. Uric acid and Hypertension: An Update with Recommendations. , 2020, American journal of hypertension.
[73] S. Asch,et al. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease , 2020, Hepatology.
[74] M. Dai,et al. Trimethylamine N-Oxide Generated by the Gut Microbiota Is Associated with Vascular Inflammation: New Insights into Atherosclerosis , 2020, Mediators of inflammation.
[75] R. Costa,et al. Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity? , 2020, Clinics and research in hepatology and gastroenterology.
[76] L. T. ’t Hart,et al. The endothelial function biomarker soluble E‐selectin is associated with nonalcoholic fatty liver disease , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[77] P. Whelton,et al. High Blood Pressure and Cardiovascular Disease , 2019, Hypertension.
[78] Hongliang Li,et al. Nonalcoholic Fatty Liver Disease , 2019, Hypertension.
[79] F. Montecucco,et al. Impact of different ectopic fat depots on cardiovascular and metabolic diseases , 2019, Journal of cellular physiology.
[80] Lei Liu,et al. Acetate Affects the Process of Lipid Metabolism in Rabbit Liver, Skeletal Muscle and Adipose Tissue , 2019, Animals : an open access journal from MDPI.
[81] O. Cummings,et al. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. , 2019, The American journal of gastroenterology.
[82] W. Ling,et al. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease. , 2019, Molecular nutrition & food research.
[83] C. Richart,et al. Circulating microbiota-derived metabolites: a “liquid biopsy? , 2019, International Journal of Obesity.
[84] Huang-Ping Yu,et al. Associations between neonatal serum bilirubin and childhood hypertension , 2019, PloS one.
[85] H. Fan,et al. The Gut Microbial Metabolite Trimethylamine N-Oxide and Hypertension Risk: A Systematic Review and Dose-Response Meta-analysis. , 2019, Advances in nutrition.
[86] Hyunyoung Jeong,et al. Characterization of Vitamin A Metabolome in Human Livers With and Without Nonalcoholic Fatty Liver Disease , 2019, The Journal of Pharmacology and Experimental Therapeutics.
[87] Roy Taylor,et al. The degree of hepatic steatosis associates with impaired cardiac and autonomic function. , 2019, Journal of hepatology.
[88] Q. Pan,et al. Trimethylamine N-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats , 2019, World journal of gastroenterology.
[89] E. Paschetta,et al. Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation , 2019, The American journal of gastroenterology.
[90] C. Borghi,et al. Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension: data from the Brisighella Heart Study. , 2019, Journal of hypertension.
[91] He-dong Lang,et al. SIRT3 Deficiency Promotes High‐Fat Diet‐Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis , 2018, Molecular nutrition & food research.
[92] G. Muscogiuri,et al. Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome , 2018, Nutrients.
[93] L. Pączek,et al. Chronic, low-dose TMAO treatment reduces diastolic dysfunction and heart fibrosis in hypertensive rats. , 2018, American journal of physiology. Heart and circulatory physiology.
[94] L. Navar,et al. Inflammation as a Regulator of the Renin-Angiotensin System and Blood Pressure , 2018, Current Hypertension Reports.
[95] D. Schuppan,et al. Predictors of advanced fibrosis in non‐cirrhotic non‐alcoholic fatty liver disease in Germany , 2018, Alimentary pharmacology & therapeutics.
[96] Houkai Li,et al. The Role of Gut Microbiota in Atherosclerosis and Hypertension , 2018, Front. Pharmacol..
[97] M. He,et al. Bidirectional association between nonalcoholic fatty liver disease and hypertension from the Dongfeng-Tongji cohort study. , 2018, Journal of the American Society of Hypertension : JASH.
[98] G. Lip,et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.
[99] R. Kurosawa,et al. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target , 2018, Circulation.
[100] Zhiye Wu,et al. Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis , 2018, Laboratory Investigation.
[101] D. Tousoulis,et al. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? , 2018, European journal of gastroenterology & hepatology.
[102] O. Giouleme,et al. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? , 2018, Current vascular pharmacology.
[103] C. Pepine,et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. , 2018, Clinical science.
[104] A. Bulmer,et al. Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea. , 2018, American journal of physiology. Heart and circulatory physiology.
[105] Y. Ilan. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment , 2018, Annals of gastroenterology.
[106] P. Strazzullo,et al. Excess Body Weight, Insulin Resistance and Isolated Systolic Hypertension: Potential Pathophysiological Links , 2018, High Blood Pressure & Cardiovascular Prevention.
[107] A. Lonardo,et al. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? , 2018, Journal of hepatology.
[108] K. Faber,et al. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD) , 2017, Nutrients.
[109] Tianxin Yang,et al. Sodium butyrate suppresses angiotensin II-induced hypertension by inhibition of renal (pro)renin receptor and intrarenal renin–angiotensin system , 2017, Journal of hypertension.
[110] S. O’Brien,et al. Aldehyde dehydrogenase 1 (ALDH1) isoform expression and potential clinical implications in hepatocellular carcinoma , 2017, PloS one.
[111] Arijit Ghosh,et al. Role of free fatty acids in endothelial dysfunction , 2017, Journal of Biomedical Science.
[112] M. Watt,et al. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance , 2017, Nature Reviews Endocrinology.
[113] A. Peters,et al. Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease , 2017, Journal of hypertension.
[114] M. Siedlinski,et al. Novel Immune Mechanisms in Hypertension and Cardiovascular Risk , 2017, Current Cardiovascular Risk Reports.
[115] B. Egan. Physical Activity and Hypertension: Knowing Is Not Enough; We Must Apply. Willing Is Not Enough; We Must Do-von Goethe. , 2017, Hypertension.
[116] B. Balkau,et al. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies , 2017, Journal of hypertension.
[117] D. Levy,et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. , 2017, Journal of hepatology.
[118] C. Pepine,et al. Hypertension-Linked Pathophysiological Alterations in the Gut , 2017, Circulation research.
[119] Zhiheng Chen,et al. Hypertension and non‐alcoholic fatty liver disease proven by transient elastography , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.
[120] E. Schleicher,et al. The impact of insulin resistance on the kidney and vasculature , 2016, Nature Reviews Nephrology.
[121] H. Ho,et al. Hepatic manifestations of women with polycystic ovary syndrome. , 2016, Best practice & research. Clinical obstetrics & gynaecology.
[122] A. Fasano,et al. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases , 2016, Tissue barriers.
[123] S. Flavahan,et al. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41. , 2016, Physiological genomics.
[124] Yingying Ding,et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis , 2016, Scientific Reports.
[125] H. Itoh,et al. The role of short-chain fatty acid on blood pressure regulation , 2016, Current opinion in nephrology and hypertension.
[126] K. Sung,et al. Fatty liver index as a simple predictor of incident diabetes from the KoGES-ARIRANG study , 2016, Medicine.
[127] A. Johnson,et al. Leptin Mediates High-Fat Diet Sensitization of Angiotensin II–Elicited Hypertension by Upregulating the Brain Renin–Angiotensin System and Inflammation , 2016, Hypertension.
[128] G. Salles,et al. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms? , 2016, International journal of molecular sciences.
[129] L. Cugusi,et al. Arterial hypertension in the female world: pathophysiology and therapy. , 2016, Journal of cardiovascular medicine.
[130] N. Zakopoulos,et al. Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive center , 2016, Clinical and experimental gastroenterology.
[131] Y. Kim,et al. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease , 2015, Medicine.
[132] Eung Ju Kim,et al. A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study , 2015, PloS one.
[133] M. Blaha,et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk , 2015, Journal of hypertension.
[134] C. Pepine,et al. Gut Dysbiosis Is Linked to Hypertension , 2015, Hypertension.
[135] Xiaofang Chen,et al. Relationship between Serum Bilirubin and Left Ventricular Hypertrophy in Patients with Essential Hypertension , 2015, PloS one.
[136] Zhen Wang,et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[137] R. Chowdhury,et al. Circulating Total Bilirubin and Risk of Incident Cardiovascular Disease in the General Population , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[138] M. Dave,et al. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability , 2015, Cellular and molecular gastroenterology and hepatology.
[139] R. Feng,et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. , 2014, World journal of gastroenterology.
[140] C. Roberts,et al. Sex-Specific Differences in Lipid and Glucose Metabolism , 2014, Front. Endocrinol..
[141] Y. Cho,et al. Clinical association between non‐alcoholic fatty liver disease and the development of hypertension , 2014, Journal of gastroenterology and hepatology.
[142] R. Brandes. Endothelial dysfunction and hypertension. , 2014, Hypertension.
[143] S. Wild,et al. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. , 2014, Journal of hepatology.
[144] H. J. Yoo,et al. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A. , 2013, Biochemical pharmacology.
[145] H. J. Yoo,et al. The effects of caloric restriction on Fetuin‐A and cardiovascular risk factors in rats and humans: a randomized controlled trial , 2013, Clinical endocrinology.
[146] M. Ermani,et al. Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[147] A. Arnold,et al. Metabolic impact of sex chromosomes , 2013, Adipocyte.
[148] F. Bushman,et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013, Nature Medicine.
[149] Y. Kesäniemi,et al. High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults , 2012, Journal of hypertension.
[150] Peter Tontonoz,et al. The Number of X Chromosomes Causes Sex Differences in Adiposity in Mice , 2012, PLoS genetics.
[151] K. Sandberg,et al. Sex differences in primary hypertension , 2012, Biology of Sex Differences.
[152] D. Stec,et al. Bilirubin, Renal Hemodynamics, and Blood Pressure , 2012, Front. Pharmacol..
[153] H. J. Yoo,et al. Effects of a three‐month combined exercise programme on fibroblast growth factor 21 and fetuin‐A levels and arterial stiffness in obese women , 2011, Clinical endocrinology.
[154] B. Graubard,et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER‐medicare database , 2011, Hepatology.
[155] R. Prough,et al. Murine hepatic aldehyde dehydrogenase 1a1 is a major contributor to oxidation of aldehydes formed by lipid peroxidation. , 2011, Chemico-biological interactions.
[156] Brian J. Bennett,et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.
[157] D. Stec,et al. Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.
[158] A. Hida,et al. Fatty liver incidence and predictive variables , 2010, Hypertension Research.
[159] Yutaka Takeda,et al. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension , 2010, BMC pulmonary medicine.
[160] L. Terracciano,et al. Predicting Fibrosis Worsening in Obese Patients With NASH Through Parenchymal Fibronectin, HOMA-IR, and Hypertension , 2010, The American Journal of Gastroenterology.
[161] G. La Torre,et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease , 2009, Hepatology.
[162] Paul L. Huang. A comprehensive definition for metabolic syndrome , 2009, Disease Models & Mechanisms.
[163] Y. Nie,et al. Prevalence of fatty liver disease and its risk factors in the population of South China. , 2007, World journal of gastroenterology.
[164] S. Bloc,et al. Bilirubin decreases NOS2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[165] R. Krauss,et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.
[166] S. Oparil,et al. Gender and Blood Pressure , 2005, Journal of clinical hypertension.
[167] V. Somers,et al. Gender-Selective Interaction Between Aging, Blood Pressure, and Sympathetic Nerve Activity , 2005, Hypertension.
[168] Andries J. Smit,et al. Autonomic Function in Hypertensive and Normotensive Subjects: The Importance of Gender , 2001, Hypertension.
[169] J F Reckelhoff,et al. Gender Differences in the Regulation of Blood Pressure , 2001, Hypertension.
[170] Alessandro Sebastian Podda,et al. Evidence of a role of endogenous estrogen in the modulation of autonomic nervous system. , 2000, The American journal of cardiology.
[171] Y. Sugiyama,et al. Gender difference in age-related changes in muscle sympathetic nerve activity in healthy subjects. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.
[172] H. Vu,et al. Association between nonalcoholic fatty liver disease and carotid intima-media thickness. , 2023, Clinica Terapeutica.
[173] T. Luedde,et al. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD) , 2023 .
[174] Ezona E Ntlahla,et al. Gut permeability is associated with hypertension and measures of obesity but not with Endothelial Dysfunction in South African youth , 2021, African Health Sciences.
[175] R. Loomba,et al. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[176] Sean M. Kearney,et al. Mining the microbiota for microbial and metabolite-based immunotherapies , 2019, Nature Reviews Immunology.
[177] R. Touyz,et al. Oxidative Stress, Inflammation, and Vascular Aging in Hypertension , 2017, Hypertension.
[178] S. Upala,et al. Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2017, Annals of hepatology.
[179] Shohei Matsuzaki,et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background , 2003, Journal of Gastroenterology.
[180] S. Grundy,et al. National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .